SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

ROIV’s mosliciguat advances to phase 3 in PH-ILD

Mosliciguat showed a 56.3% reduction in PVR and improvements in 6MWD and NT-proBNP in PH-ILD patients, with favorable safety and once-daily dosing. A phase 3 trial is underway to evaluate efficacy and safety further.

ROIV

Mosliciguat demonstrated a 56.3% reduction in PVR and significant improvements in 6MWD and NT-proBNP in PH-ILD patients, with a favorable safety profile and convenient once-daily dosing. A phase 3 trial is underway to further evaluate its efficacy and safety.Original document: Roivant Sciences Ltd…

Related stories